Therapeutic Response

5q deletion status confers therapeutic sensitivity to Lenalidomide in patients with Myeloproliferative Neoplasm.

Statements

Source and description
Revlimid (lenalidomide) [product information]. EMA. The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.